Management of Central Nervous System Vasculitis in Rheumatoid Arthritis
Induction Therapy
- For adult patients with rheumatoid arthritis who develop CNS vasculitis, start high‑dose intravenous methylprednisolone 500–1000 mg daily for 3 days, then continue oral prednisolone 1 mg/kg/day (maximum 60–80 mg) together with either cyclophosphamide or rituximab as remission‑induction therapy. 1
Choice of Immunosuppressive Agent
Cyclophosphamide
- Cyclophosphamide may be given orally at 2 mg/kg/day (maximum 200 mg) or as monthly intravenous pulses of 0.6 g/m²; this regimen is supported by Level 1A evidence for life‑threatening vasculitic disease. 2
Rituximab
- Rituximab is administered at 375 mg/m² intravenously weekly for four weeks and is an evidence‑based alternative (Level 1B) to cyclophosphamide, especially when fertility preservation is a concern. 1
Mycophenolate Mofetil (alternative)
- Mycophenolate mofetil 2 g daily combined with glucocorticoids has achieved complete neurological recovery and MRI resolution in a documented case; it carries a Grade C recommendation for non‑organ‑threatening disease, although CNS involvement is generally considered organ‑threatening. 3
Critical Supportive Measures
Infection Prophylaxis
- Provide Pneumocystis jirovecii prophylaxis with trimethoprim‑sulfamethoxazole (alternating‑day or daily dosing) for all patients receiving cyclophosphamide or high‑dose steroids. 2
- Co‑administer MESNA with cyclophosphamide to prevent hemorrhagic cystitis, and ensure aggressive hydration (oral or intravenous) on infusion days. 2
Monitoring Strategy
- Do not use serial ANCA titers or rheumatoid‑factor levels to guide treatment changes; base adjustments on structured clinical neurological assessment and MRI findings. 3
- Monitor complete blood counts regularly during cyclophosphamide therapy. 2
Maintenance Therapy
- Continue remission‑maintenance therapy for at least 24 months after achieving sustained remission. 3
- When cyclophosphamide is contraindicated or unavailable, azathioprine or mycophenolate mofetil may be used as alternative maintenance agents. 3